US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Precedential US Federal Court Decision Hands SNIPR Biome a win in patent appeal over Rockefeller University for CRISPR-Cas microbial gene editing

· Five contested patents held by SNIPR remain in place  · Precedential ruling means that SNIPR’s patent portfolio will not be subject to any further interference and will not be judged by the old first-to-invent standardCopenhagen, July 17[th] 2023: SNIPR Biome ApS, the company pioneering CRISPR-based microbial gene therapy, announces today the United States Court of Appeals for the Federal Circuit has issued a precedential ruling in favor of SNIPR in a patent interference case with Rockefeller University.   The patent interference case focused on one allowed patent application

SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy

· SNIPR001 demonstrates proof of principle in reducing E. coli levels in the human gastrointestinal tract · SNIPR001 is a novel CRISPR-Cas therapeutic, selectively targeting antibiotic-resistant E. coli which can cause life-threatening infections in vulnerable hematological cancer patients  · Future studies needed to evaluate the impact of SNIPR001 on reducing the rate of E. coli infections in high-risk cancer patientsCopenhagen, May 31, 2023: SNIPR Biome ApS (“SNIPR”), the company pioneering CRISPR-based microbial gene therapy, today announces positive interim clinical results from

SNIPR Biome's data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology

· SNIPR001 is a novel CRISPR-Cas therapeutic designed to selectively target antibiotic resistant E. coli, which can cause fatal infections in vulnerable hematological cancer patients   · SNIPR001 represents the first CRISPR- therapeutic developed to specifically remove E. coli in the human gut   · In vitro studies showed SNIPR001 displaying high specificity towards E. coli and activity in multi-drug resistant strainsCopenhagen, May 4 2023: SNIPR Biome ApS (“SNIPR”), the company pioneering CRISPR-based microbial gene therapy, announces today that Nature Biotechnology has published (

SNIPR Biome further strengthens CRISPR/Cas IP portfolio with patent grant

SNIPR Biome further strengthens CRISPR/Cas IP portfolio with patent grant   · Patent issuance adds to SNIPR’s extensive intellectual property portfolio, comprising more than 60 granted worldwide patents, including in the USA and Europe · Patent covers the use of killing of bacteria at least 1000-fold in a microbiome using any CRISPR/Cas system · USPTO has also issued a Notice of Allowance for methods of using CRISPR lytic phage   Copenhagen, December 22 2022: SNIPR Biome ApS (“SNIPR” or “the Company”), the company pioneering CRISPR-based microbial gene therapy, announces

SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001

Copenhagen, April 20th, 2022: SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, today announced dosing of the first human subjects in its phase 1 clinical trial with SNIPR001, an orally administered CRISPR-based therapeutic. The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut. The study plans to enroll 36 healthy volunteers for multiple ascending dosing of SNIPR001 (NCT05277350). SNIPR001 has been granted Fast-Track

SNIPR BIOME expands its Executive Management team and opens offices in the US and UK

Copenhagen, March 16th, 2022: SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, today announced the appointment of Jasper Clube as Chief Intellectual Property Officer from 1 February 2022 and Stephanie Krebs as Chief Business Officer from 14 March 2022. In addition, SNIPR Biome will open offices in the US and the UK effective immediately. ”We are extremely pleased to add two strong life science profiles such as Stephanie and Jasper to our Executive Management Team. Both have a proven successful track record within biotech, and marks the entering of a new

SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark

Copenhagen, March 8th, 2022: SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is opening a 175 square meter state-of-the-art BSL2/GMO2-classified laboratory in Copenhagen. The new facilities will be among the largest GMO2 laboratories in Scandinavia and Northern Europe with the capacity to handle clinical samples from the phase 1 clinical trial with SNIPR001 and expand the company’s CRISPR and microbiome portfolio. Placing the laboratory in Denmark was not a coincidence, but a strategic choice. “The Danish life science environment is incredibly strong, which makes

SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients.

Copenhagen, January 25th, 2022: SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for SNIPR001. SNIPR001 is the company’s first development candidate targeting E. coli in patients with hematological malignancy at risk of neutropenia. This announcement comes only a few weeks after the FDA approved the Investigational New Drug (IND) Application paving the way initiating the first clinical trial in humans.  ”At SNIPR BIOME, we are extremely proud to have been granted Fast Track

SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections

Copenhagen, January 11th, 2022: SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) Application, for our first development candidate, enabling the company to initiate the first clinical trial in humans with SNIPR001. The trial, which is scheduled to begin in first half of 2022, will investigate safety and tolerability in healthy volunteers, and investigate the effect of SNIPR001 on E. coli colonisation in the gut.   “The SNIPR BIOME team is excited

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media